Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-LCRP-PCOSA: DOD Lung Cancer, Patient-Centered Outcomes and Survivorship Award

Closed Closed August 10, 2023 Opportunity HT9425-23-LCRP-PCOSA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$2.1 million
• Expected awards2
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The Patient-Centered Outcomes and Survivorship Award (PCOSA) mechanism is being offered for the first time in FY23. The Patient-Centered Outcomes and Survivorship Award supports high-risk, high-reward research studies that span the spectrum of behavioral health science, survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, co-morbid conditions, and examining the physical, psychological, social, and economic effects of lung cancer among patients and their families. The overall intent of the FY23 LCRP Patient-Centered Outcomes and Survivorship Award is to promote evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research studies may include, but are not limited to: Studies to examine and improve quality of life, decision-making, and symptom and side effect management (e.g., toxicity of treatment, palliative/supportive care, psychological distress and anxiety). • Studies to investigate the impact of prevention, diagnostics, treatment, or health care delivery approaches on health outcomes. • Studies to assess the relationship(s) between behavioral, cognitive, and/or social functioning in relation to lung cancer detection, initiation, progression, treatment, and rehabilitation. • Studies into the psychological health and well-being of those affected by lung cancer (e.g., patients, family members). • Development and testing for efficacy of lifestyle interventions and symptom management approaches to minimize disease risk and maximize quality of life. Key aspects of this award mechanism are: • Impact: The Patient-Centered Outcomes and Survivorship Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will accelerate the movement of promising ideas into clinical applications, generate knowledge to improve clinical guidelines, or significantly advance behavioral, cognitive, and/or social functioning related to the target population. • Study Design: Applications should clearly articulate the chosen design of the study.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.